India, March 31 -- In a significant move to drive awareness about precision oncology as an essential, accessible and affordable treatment plan for lung cancer treatment, LuNGS Alliance, an initiative led by the Cancer Research and Statistic Foundation (CRSF), has announced free Lung NGS (Next Generation Sequencing) biomarker testing for lung cancer patients across India.

This initiative is backed by leading pharmaceutical companies AstraZeneca, Pfizer, and Roche, with 4baseCare serving as the official lab partner.

The TARGT First Solid test by 4baseCare offers a comprehensive analysis of 72 commonly mutated genes, identifying actionable biomarkers that enable personalized treatment plans based on a patient's unique genomic profile. This...